Amylin (AMLN +47.6%) soars to $22.71 after Bloomberg reports the diabetes drugmaker turned down...

|By:, SA News Editor

Amylin (AMLN +47.6%) soars to $22.71 after Bloomberg reports the diabetes drugmaker turned down a $22/share bid from Bristol-Myers Squibb (BMY) earlier this year. It's added Bristol-Myers hasn't approached Amylin since the rejection, and the latter company is focused on finding an international marketing partner for its products.